Identifying Crude Drugs in Kampo Medicines Associated with Drug-Induced Liver Injury Using the Japanese Adverse Drug Event Report Database: A Comprehensive Survey

Author:

Kimura Kyosuke12,Kikegawa Mami13,Kan Yusuke14,Uesawa Yoshihiro1ORCID

Affiliation:

1. Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose 204-8588, Japan

2. Datack, Inc., Tokyo 102-0072, Japan

3. Department of Kampo Medicine, Yokohama University of Pharmacy, Yokohama 245-0066, Japan

4. Nanohana Pharmacy, Tomakomai 053-0021, Japan

Abstract

The current study aimed to identify the crude drugs associated with drug-induced liver injury (DILI) in 148 Kampo medicines prescribed throughout Japan using the Japanese Adverse Drug Event Report (JADER) database, a large-scale spontaneous reporting system in Japan. First, we tabulated the number of DILI reports from the report-based dataset and the background information from the patient-based dataset. Thereafter, we combined the 126 crude drugs into 104 crude drug groups to examine multicollinearity. Finally, the reporting odds ratios (RORs), 95% confidence intervals, p values for Fisher’s exact test, and number of reports were calculated for each crude group to identify those associated with DILI. Notably, the number of adverse event reports for DILI (63,955) exceeded that for interstitial lung disease (51,347), the most common adverse event. In total, 78 crude drug groups (90 crude drugs) were reported to have an ROR > 1, a p < 0.05, and ≥10 reported cases. Our results highlight DILI as an essential issue, given that it was among the most frequently reported adverse drug reactions. We were able to clearly identify the crude drugs associated with DILI, which could help manage adverse drug reactions attributed to Kampo medicines and crude drugs.

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference73 articles.

1. Adverse Effects of Kampo Medicines;Shimada;Intern. Med.,2022

2. Ministry of Health, Labour and Welfare (2023, April 15). The Approval Standards for OTC Kampo Products (Revised March 2019) (in Japanese), Available online: https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/0000160072.pdf.

3. Japan Kampo Medicines Manufacturers Association (2023, March 10). Kampo Medicines for Prescription 2022-Informations on Package Inserts of 148 Formulations-Usability Research Subcommittee, Ethical Kampo Products Committee, Japan Kampo Medicines Manufacturers Association (JKMA) (in Japanese). Available online: https://www.nikkankyo.org/seihin/seihin1.htm.

4. Japan Kampo Medicines Manufacturers Association (2023, March 10). Actual Condition Survey of Kampo Prescriptions on 18 October 2011 (in Japanese). Available online: https://www.nikkankyo.org/serv/pdf/jittaichousa2011.pdf.

5. Recurrent Drug-induced Liver Injury Caused by the Incidental Readministration of a Kampo Formula Containing Scutellariae Radix;Shimada;Intern. Med.,2018

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3